Richard has more than 30 years continuous working experience in private practice. He has encountered a broad and varied spectrum of possible situations and scenarios involving all sorts of IP challenges and requirements.
Certain essential elements of patent work align well with Richard's character. He enjoys the sense of chase he gets in fact finding and "stone turning". This means Richard is very adept at peeling back the layers of any matter to get quickly to the heart of it, legally, technically and commercially. He also has a particularly well-honed radar for identifying risk and opportunity, and then a creative imperative and internal driver to match. Richard finds the combinations of these skills serves him well in generating excellent cost effective commercial solutions to whatever patent challenges he is presented with.
Broadly, Richard's technical knowledge and experience comes under IPC codes: A01, A21, A22, A23, A24, A61, B01, B09, B82, C02, C04, C11, C12 (C12N, C12 Q), C13, C25 and C40.
More specifically: CRISPR; gene editing; riboswitches, nucleic acid sequencing; PCR based assays; nucleic acid-based diagnostics; antibodies (therapeutic or diagnostic), immunoaffinity purification; chimeric T cells and therapies; miRNA, siRNA, oncology; biomarkers; bioinformatics; enzymes; epigenetics; modified bacteria, viruses, algae, fungi, plants, insects (mosquitoes), fish and fish feed, animals, plant secondary compounds; oligosaccharides; pest control; plant breeding tools; plant protection products; biodegradable packaging; sewage treatments; human pharmaceutical formulations (small molecules, proteins, antibodies); vaccines (anticancer, influenza); medical devices; ocular devices, diagnostics and therapies.
Natural Science (Oxon)
Patent Litigation (Nottingham Trent)
Plant Science (Wales)
“…excellent knowledge, experience and analytical acumen…”. (Legal 500 - 2011) “…superb…”’ (Legal 500 - 2012)
November 28th 2019
November 28th 2019
June 3rd 2019
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.